Manager / Senior Manager of Accounting, Valo Health
More information about location
Office located in Lexington, MA
Platform for drug development and discovery
Be an early applicant
Platform for drug development and discovery
101-200 employees
Be an early applicant
More information about location
Office located in Lexington, MA
101-200 employees
Company mission
To make the drug discovery and development process faster, less expensive, and with a higher probability of success.
Role
Who you are
- Minimum of 5 years with at least 2 years of Big Four experience
- BS/BA degree in accounting, or equivalent
- Knowledge of U.S. GAAP, CPA required
- Agility to expand your role, scale accounting operations and manage direct reports as Valo grows into a larger, more complex company
- Excellent communication and interpersonal skills
- Commitment to ethical behavior and adherence to all company policies and statutory requirements
- Strong planning and problem-solving skills
- Attention to detail and pride in maintaining high-quality financial data
- Team-oriented, collaborative, flexible and willing to adapt to changing needs and timelines
- Advanced Excel skills required
- Biopharma experience a plus
- Experience in Valo’s accounting/finance systems a plus (NetSuite, FloQast, Prendio, Adaptive Insights)
What the job involves
- Reporting to the Controller, the Manager / Senior Manager of Accounting will lead monthly, quarterly and annual close processes and ensure the accuracy, timeliness, and integrity of financial data
- Lead monthly, quarterly and annual close activities by ensuring timely, accurate and complete financial records and reporting in accordance with US GAAP, legal requirements, and the Company’s corporate policies
- Collaborate with other members of the Finance team in the preparation of internal reporting package and other reports
- Responsible for error-free monthly journal entries, analysis, balance sheet reconciliations, reports, and financial statements
- Analyze and provide commentary on balance sheet and income statement variances
- Lead corporate consolidations, overseeing subsidiary reporting requirements
- Oversee maintenance of Valo’s fixed assets records in accordance with the Company’s fixed asset capitalization policy, calculate monthly fixed asset depreciation, and prepare related monthly, quarterly, and annual schedules
- Ensure that accounting documentation is compiled and maintained in support of legal, regulatory, and audit requirements
- Support and assist with quarterly reviews and annual audits or any ad hoc projects as directed by the Controller
- Maintain the general ledger, including account and project coding system
- Prepare annual reports and filings (e.g., property tax, etc.) as needed
- Proactively identify emerging business and technical risks, issues and developments in a timely manner for action and incorporation into the SOX compliance program documentation
- Assist with preparation of annual SOX risk assessment, including determining materiality, identifying in-scope processes and significant accounts and linking key assertions
- Interface with external auditors for annual audits, quarterly reviews and internal control audits, including preparation of required schedules and documentation
- Participate in special projects or ad-hoc analysis in support of the finance department and company initiatives
Our take
Drug development is a critical component of health care. Reducing costs, improving discovery processes, and accelerating drug development are all critical to success in the drug pipeline. Using human-centric data and ML-anchored computation, Valo Health’s integrated drug development platform, known as Opal, improves outcomes in drug development, by leveraging advanced data analysis.
Drug development entails a variety of steps including molecule discovery, clinical development, and target discovery. With the vast amount of data that is generated, a system like Opal incentivizes investment in outcomes that are more likely to correspond with effective treatments. This reduces the number and expense of clinical trials needed to demonstrate drug effectiveness.
There are a variety of competitors in the data-driven drug discovery field, including insitro, Atomwise, and Exscietia, but this vast market should still offer enough space for Valo Health to grow. In 2021, the company experienced a set-back in the surprise calling off of a merger that would have seen it go public, but despite this has continued to operate well and advance towards its goal of transforming the drug development process.
Freddie
Company Specialist at Welcome to the Jungle
Insights
-23% employee growth in 12 months
Company
Funding (last 2 of 7 rounds)
Nov 2021
$1m
LATE VC
Jul 2021
$33.5m
LATE VC
Total funding: $487.5m
Company benefits
- Medical, Dental, and Vision Insurance
- Flexible Time-off
- 401K
- Corporate Engagement Opportunities with Local Non-Profit Organizations
- Commuter Reimbursement
- Fitness Reimbursement
- Pet Insurance
Company HQ
Back Bay East, Boston, MA
Leadership
Brian Alexander
(CEO)Also a Partner at Flagship Pioneering. Previously SVP of Genentech, CEO of Foundation Medicine and was a n Associate Professor at Harvard Medical School.
Brett Blackman
(COO)Member of the Board of Directors at Stanley Manne Children's Research Institute. Previously Interim Chief Scientific Officer at Omega Therapeutics and was a Strategic R&D Advisor at Ohana Biosciences, Inc.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job
View 1 more job at Valo Health